XOMA Royalty Corporation has extended its offer to purchase all outstanding common shares of LAVA Therapeutics N.V. until one minute after 11:59 p.m. Eastern time on November 12, 2025. The extension follows a previously announced share purchase agreement between the two companies. According to LAVA Therapeutics N.V., the outcome of the offer depends on a sufficient number of shares being tendered by the new deadline. If the offer is not completed, LAVA's management has indicated that liquidation and dissolution may be considered, with estimated proceeds to shareholders likely to be significantly less than the offer's cash consideration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LAVA Therapeutics NV published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.